Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Overweight from Equal Weight at Barclays with analyst Brandon Oglenski saying the company appears to have all the attributes of a "value compounding opportunity" for equity investors. 2. Mindbody (MB) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brent Bracelin saying elevated churn risk from the company's model transition to higher-value subscribers is now discounted into the valuation. 3. Enviva (EVA) upgraded to Buy from Neutral at Citi with analyst Ryan Levine saying he likes the risk/reward at current levels and believes Enviva is well positioned in the next 12-18 months. 4. PSEG (PEG) upgraded to Overweight from Equal Weight at Barclays with analyst Gregg Orrill saying the company could be the industry's largest beneficiary of potential near-term policy initiatives. 5. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Bernstein with analyst Tim Anderson saying that the outlook of its current products has improved, leaving it well-positioned to grow even if its pipeline does not yield any new drugs through 2025. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.